A one-time colonoscopy for screening entailed an 18% risk reduction of incidence in colorectal cancer (CRC) compared with no screening.
Both antibiotic use and days with antibiotic use could be markedly reduced with the help of a procalcitonin-based algorithm.
Early surgery might benefit Crohn's patients, but identifying exact patient groups who will benefit from early surgery requires prospective studies.
Compared to conventional colonoscopy, the addition of artificial intelligence entailed significantly higher detection and lower rates of missed adenomas.
Symptom control maintenance after 40 weeks was investigated in mirikizumab responders after a 12 week induction therapy.
Significantly less ulcer bleeding was found in patients with chronic aspirin use who underwent eradication of Helicobacter pylori, according to HEAT trial results.
In the phase 3 EoE KIDS trial, dupilumab showed remarkable efficacy in paediatric patients with eosinophilic oesophagitis.
For the first time, a study assessed longitudinal changes in microbiota during therapy with immune checkpoint inhibitors (ICIs).
Follow-up >6 months for necrotising pancreatitis infections with immediate or delayed drainage showed no influence on mortality or major complications.
Crohn's patients who responded only after a risankizumab second induction kept a CDAI clinical response in 75.8% on subcutaneous 360 mg at week 52.
Upadacitinib led to remission rates and endoscopic response in almost half of intensively pretreated patients with moderate-to-severe Crohn's at week 12.
A study revealed that pancreatic cancer was initially missed in CT or MRI scans in 7.7% of the affected patients, reducing chances of curative surgery.
A new Europe-wide study highlights the worrying increase in the prevalence of various digestive diseases since 2000.
Maintenance therapy with an higher dose interval of adalimumab resulted in similar persistent flare rares in Crohn's Disease patients in stable remission.
Though widely used in Japan, in Europe its application has been on the rise in recent years: How can colorectal ESD help in gastroenterology?
Etrasimod leads to significant reductions in T and B cell subsets and paralleled reductions in absolute lymphocyte counts, showed the ELEAVATE trials.
H. pylori is considered the main cause of gastric cancer. If we eradicate it, other stomach-related diseases may become rarer. Are we close to achieving this?
+52 weeks of upadacitinib therapy for ulcerative colitis outperformed placebo in endpoints like clinical, histological, and patient-reported outcomes.
Primary sclerosing cholangitis patients who received colectomy with ileostomy had a higher survival chance without liver transplant than those without surgery.
Therapy with mirikizumab leads to a higher percentage of patients achieving resolution of active colonic inflammation with absence of neutrophils at induction.